Hussman Strategic Advisors Inc. Sells 63,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Hussman Strategic Advisors Inc. trimmed its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 60.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,000 shares of the biopharmaceutical company’s stock after selling 63,000 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in TG Therapeutics were worth $1,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in TG Therapeutics by 35.8% in the third quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company’s stock worth $212,712,000 after acquiring an additional 2,398,015 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in TG Therapeutics by 0.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company’s stock worth $27,708,000 after purchasing an additional 7,939 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of TG Therapeutics by 7.5% during the 4th quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company’s stock worth $24,989,000 after purchasing an additional 57,996 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after buying an additional 270,286 shares during the last quarter. Finally, Braun Stacey Associates Inc. bought a new position in TG Therapeutics during the fourth quarter valued at about $13,328,000. Institutional investors own 58.58% of the company’s stock.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. This trade represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Price Performance

TGTX stock opened at $31.01 on Thursday. The firm has a 50 day moving average of $31.09 and a 200-day moving average of $27.61. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $4.83 billion, a P/E ratio of -310.07 and a beta of 2.26. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.